Brighton Jones LLC Acquires 577 Shares of Eli Lilly and Company (NYSE:LLY)

Brighton Jones LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,674 shares of the company’s stock after buying an additional 577 shares during the quarter. Brighton Jones LLC’s holdings in Eli Lilly and Company were worth $5,639,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of LLY. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company in the third quarter worth $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc bought a new stake in Eli Lilly and Company in the third quarter worth $40,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $44.36 on Tuesday, hitting $781.56. 7,432,651 shares of the company’s stock traded hands, compared to its average volume of 3,071,009. The firm’s 50-day moving average price is $760.89 and its two-hundred day moving average price is $668.00. The firm has a market capitalization of $742.61 billion, a PE ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the business posted $2.09 EPS. The company’s revenue was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $731.55.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.